Acambis plc

Acambis Q3 results

Friday, 18 November 2005

Acambis had lower revenues and bigger loses, as expected with the winding down of its largest contract to date - with the US government for smallpox vaccine.
As with other early-stage pharmaceutical companies, most of Acambis’ value lies in its drug pipeline. Both its Japanese encephalitis virus and its West Nile virus have entered phase three […]

[more]

Acambis

Tuesday, 11 January 2005

Vaccine manufacturer Acambis is a difficult company to value: new contracts for smallpox vaccine (its main source of revenues at the moment) are uncertain, while its travel vaccines are largely still being developed or tested, with only one currently actually being sold.

[more]